Business Overview: Aadi Bioscience, Inc. (NASDAQ: AADX)

---

Executive Summary

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company focused on precision therapies for cancers and other diseases driven by hyperactivation of the mTOR pathway. The company's lead and only approved product, FYARRO® (nab-sirolimus), is the first and only FDA-approved treatment for advanced malignant perivascular epithelioid cell tumor (PEComa), an ultra-rare soft-tissue sarcoma. Headquartered in Pacific Palisades, California, Aadi is a small, focused organization that is now attempting to expand nab-sirolimus into a broader population of tumors defined by genomic biomarkers (TSC1/TSC2 mutations) rather than tumor location — a "tissue-agnostic," biomarker-first approach to oncology.

---

1. Core Business Model & How They Work

Aadi operates the classic small-cap, single-asset biopharma model: commercialize a narrow, FDA-approved rare-disease indication to generate cash flow while running clinical trials to expand the label into larger, adjacent, biomarker-defined populations.

[ Genomic Biomarker Hypothesis (TSC1/TSC2 loss → mTOR hyperactivation) ]
        ➡ [ FYARRO approved in ultra-rare PEComa ]
        ➡ [ Commercial sales to fund pipeline ]
        ➡ [ Biomarker-selected trials in bladder cancer & other solid tumors (PRECISION1) ]
        ➡ [ Potential label expansion / partnerships ]

Key Operational Drivers

1. Biomarker-Driven Precision Oncology: Rather than developing drugs by tumor type, Aadi targets any tumor carrying TSC1/TSC2 mutations, a genomic signature found across bladder, kidney, and other cancers.
2. Orphan Drug Commercialization: FYARRO's approval in advanced malignant PEComa (an indication affecting only a few hundred patients diagnosed annually in the U.S.) gives Aadi orphan drug exclusivity and a small, targeted sales force model rather than a large commercial infrastructure.
3. Capital-Efficient Pipeline Expansion: Cash generated from FYARRO sales, together with existing capital, funds label-expansion studies (notably the PRECISION1 trial in metastatic urothelial/bladder cancer) rather than a broad multi-asset pipeline.

---

2. Product Portfolio & Pipeline

---

3. Competitive Landscape

                     High Selectivity / Biomarker-Defined
                                    │
      Everolimus (Afinitor) ───────┼──────── FYARRO (nab-sirolimus)
      (older, oral mTOR inhibitor, │          (albumin-bound, IV,
       broad label, generic risk)  │           PEComa-specific label)
                                    │
      ─────────────────────────────┼───────────────────────────────
                                    │
      Broad-spectrum oncology      │        Rare-tumor specialists
      (large pharma pipelines)     │        (Springworks, Day One
                                    │         Biopharmaceuticals)

Competitors by Domain

mTOR-pathway oncology

• Key Competitors: Novartis/generic everolimus (Afinitor), other rapalogs, and next-generation mTOR/PI3K-AKT-mTOR pathway inhibitors from large pharma.
• Dynamics: Aadi's advantage is a formulation (albumin-bound nanoparticle sirolimus) with better pharmacokinetics/tolerability than oral rapalogs, plus a first-mover, FDA-approved label specifically in PEComa — a niche too small for large-cap competitors to prioritize.

Rare/genomically-defined solid tumor therapeutics

• Key Competitors: SpringWorks Therapeutics (rare tumor specialist, e.g., desmoid tumors), Day One Biopharmaceuticals (pediatric/rare oncology), and any large pharma running basket trials in TSC1/TSC2-altered cancers.
• Dynamics: Aadi competes for clinical trial patients, KOL mindshare, and payer attention in an ultra-niche but underserved genomic segment.

---

4. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• Regulatory exclusivity: Orphan drug designation and being the sole approved therapy for advanced malignant PEComa creates a de facto monopoly in that indication.
• Formulation IP: Albumin-bound nanoparticle technology applied to sirolimus is patent-protected and difficult to replicate cheaply.
• Biomarker-first R&D thesis: A defensible scientific rationale (TSC1/TSC2 loss-of-function driving mTOR hyperactivation) that can, if validated in bladder cancer, open a materially larger addressable market than PEComa alone.

Strategic Risks & Vulnerabilities

1. Extremely small commercial base: PEComa is vanishingly rare, so current FYARRO revenue is modest and provides limited runway without pipeline success.
   • Mitigation Strategy: Aggressive pursuit of the PRECISION1 bladder cancer expansion to access a much larger patient population.
2. Single-asset concentration risk: Nearly all corporate value rests on one molecule (nab-sirolimus) across a handful of indications.
   • Mitigation Strategy: Diversify into multiple genomically-selected tumor types using the same asset, spreading clinical and commercial risk without needing a new molecule.
3. Clinical trial execution risk: Success in PEComa does not guarantee similar efficacy signals in bladder or other cancers.
   • Mitigation Strategy: Biomarker-selected (TSC1/TSC2-mutant) enrollment aims to enrich for responders and improve trial odds versus an all-comers design.

---

5. Financial Overview & Performance Matrix

---

6. Summary Conclusion

Aadi Bioscience is best understood as an option on a scientific thesis: that mTOR hyperactivation driven by TSC1/TSC2 loss is a targetable vulnerability across multiple solid tumors, not just the ultra-rare PEComa indication where FYARRO is already approved and generating real, if modest, commercial revenue. That existing approval provides both non-dilutive cash flow and clinical/regulatory credibility that a purely pre-commercial biotech would lack.

The company's central strategic question is whether the PRECISION1 trial and other TSC1/TSC2-selected studies can convert a proof-of-concept in an ultra-rare sarcoma into a genuinely larger franchise in bladder cancer and beyond. Success would transform Aadi from a niche orphan-drug company into a broader precision-oncology player; failure would leave it a profitable-but-small single-indication business exposed to the risks of any single-product company.